AstraZeneca, in alliance with Saint Luke’s Mid America Heart Institute, has started a Phase III clinical trial of its diabetes drug Farxiga (dapagliflozin) to treat hospitalised Covid-19 patients at risk of serious complications.

Farxiga is an oral, once-daily sodium-glucose transport protein 2 (SGLT2) inhibitor indicated for adults with insufficiently controlled type 2 diabetes (T2D), as an adjunct to diet and exercise.

The new randomised, global trial, named DARE-19, will evaluate the drug’s ability to reduce the risk of disease progression, clinical complications, and death from Covid-19 in patients with CV, metabolic or kidney risk factors.

Read the full article here